London32 trials: AI cut cardiac all-cause mortality 16%.
Decision-support systems reduced mortality and improved medication adherence by 59% across 27 meta-analysed trials.
Workflow AI cut diagnostic time by up to 120 seconds and hospital stays by up to 4 days.
Sources: Nature
WHY CARDIOLOGY FIRST
Cardiology generates more structured digital data than almost any other specialty — ECGs, echocardiograms, continuous telemetry, lab panels. Pattern-recognition models thrive on dense numerical streams, which is why cardiac AI has crossed clinical thresholds years before fields like psychiatry or rheumatology.
WHAT META-ANALYSIS ACTUALLY DOES
Pooling 32 trials does not just add sample size — it averages out the idiosyncrasies of any single hospital, protocol, or patient mix. A 16% mortality signal that survives meta-analysis is structurally stronger than the same number from one large trial, because it has already been stress-tested across heterogeneous settings.
THE ADHERENCE PROBLEM
Roughly half of patients prescribed cardiac medications stop taking them within a year. This is the largest single source of preventable cardiac death in the developed world — bigger than surgical error, bigger than misdiagnosis. A 59% adherence improvement, if it holds in deployment, would matter more than most new drugs.
WHY 120 SECONDS MATTERS
In acute coronary syndrome, the doctrine is 'time is muscle' — every minute of delayed reperfusion kills heart tissue that does not regrow. Door-to-balloon time targets are measured in single-digit minutes. Two minutes shaved off triage diagnostics is not a workflow nicety; it is salvaged myocardium.
THE FRAMINGHAM INHERITANCE
Modern cardiac risk scoring descends from the Framingham Heart Study, started in 1948 — the longest continuous cohort study in medicine. AI risk models are trained on its descendants (UK Biobank, MESA, ARIC). The algorithms are new; the underlying epidemiological scaffolding is three generations old.
THE REGULATORY GAP
The FDA has cleared over 700 AI/ML-enabled medical devices, the majority in radiology and cardiology. But almost all are cleared via the 510(k) pathway — demonstrating 'substantial equivalence' to a predicate device, not running a randomized trial. The 32-trial body of evidence here is unusual precisely because most deployed cardiac AI never went through anything like it.